Verma Ritika, Bhardwaj Shefali, Lathia Tejal, Kalra Sanjay, Ranadive Ruchira, Tanna Snehal, Padsalge Mahesh, Juneja Archana, Samundra Kirti, Thakkar Piya Ballani, Jain Vandana, Kini Vishal, Kothari Sneha, Guntur Saimala, Joshi Shilpa, Singal Arbinder
Fitterfly Healthtech Pvt Ltd, Akshar Blue Chip Corporate Park Turbhe MIDC, Navi Mumbai, 400705 India.
Apollo Hospital, Navi Mumbai, 400614 India.
Int J Diabetes Dev Ctries. 2023 Jun;43(3):425-432. doi: 10.1007/s13410-022-01111-1. Epub 2022 Jul 22.
Lifestyle modification is an integral aspect for the management of type 2 diabetes (T2D). However, it is difficult to ensure the accuracy of personalized lifestyle advice. The study aims to analyse the real-world effectiveness of personalized glycemic response based Diabefly-Pro digital therapeutics for better glycemic control.
Data from continuous glucose monitoring (CGM) of 64 participants with T2D was analysed. All participants were provided with modified lifestyle plan based on their personalized glycemic response. The CGM data was analysed for a period of 7 days, before and after the introduction of modified lifestyle plan. Primary outcome of the study was change in time in range (TIR). Secondary outcomes of the study were change in mean blood glucose, time above range (TAR), time below range (TBR) and glucose management indicator (GMI).
Significant improvement in glycemic control was observed after the introduction of personalized lifestyle plan. Median reduction in mean blood glucose was from 139.5 (118.3 to 169.3) mg/dL to 122.0 (101.5 to 148.8) mg/dL ( < 0.0001). TIR and GMI improved from 70.50 (50.75 to 83.50) % to 75.00 (58.25 to 89.00) % ( = 0.0001) and 6.64 (6.13 to 7.35) % to 6.23 (5.74 to 6.86) % ( < 0.0001) respectively. TAR reduced significantly from 17.00 (4.25 to 38.0) % to 6.00 (1.25 to 26.0) % ( < 0.0001). No significant increase in TBR was observed ( = 0.198).
Personalized glycemic response-based Diabefly-Pro digital therapeutics program was effective in achieving better glycemic control in people with T2D.
生活方式的改变是2型糖尿病（T2D）管理的一个重要方面。然而，很难确保个性化生活方式建议的准确性。本研究旨在分析基于个性化血糖反应的Diabefly-Pro数字疗法对改善血糖控制的实际效果。
分析了64名T2D参与者的连续血糖监测（CGM）数据。根据参与者的个性化血糖反应为他们提供了改良的生活方式计划。在引入改良生活方式计划之前和之后，对CGM数据进行了为期7天的分析。该研究的主要结果是血糖在目标范围内时间（TIR）的变化。该研究的次要结果是平均血糖的变化、高于目标范围时间（TAR）、低于目标范围时间（TBR）和血糖管理指标（GMI）。
引入个性化生活方式计划后，血糖控制有显著改善。平均血糖的中位数从139.5（118.3至169.3）mg/dL降至122.0（101.5至148.8）mg/dL（<0.0001）。TIR和GMI分别从70.50（50.75至83.50）%提高到75.00（58.25至89.00）%（P = 0.0001）和从6.64（6.13至7.35）%提高到6.23（5.74至6.86）%（<0.0001）。TAR从17.00（4.25至38.0）%显著降至6.00（1.25至26.0）%（<0.0001）。未观察到TBR有显著增加（P = 0.198）。
基于个性化血糖反应的Diabefly-Pro数字疗法计划对实现T2D患者更好的血糖控制有效。
